On May 2, 2019 Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, reported that the company plans to participate in the following conferences in May (Press release, Iovance Biotherapeutics, MAY 2, 2019, View Source;p=irol-newsArticle&ID=2396790 [SID1234535570]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NYAS Frontiers in Cancer Immunotherapy in New York, May 14-15, 2019
Panel Presentation: Will CAR-T Cell Therapies, Bispecific Antibodies, or TILs Be More Beneficial for Solid Tumors?
Session: Session 4, Breakout Track B
Location: The New York Academy of Sciences
Date/time: Wednesday, May 15, at 1:00 p.m. EDT

Oppenheimer Oncology Insight Summit in New York, May 16, 2019
Location: InterContinental New York Barclay Hotel

AACR Bladder Cancer: Transforming the Field Conference in Denver, May 18-21, 2019
Poster Presentation: Expansion of tumor-infiltrating lymphocytes (TIL) using Iovance’s Gen 2 process from advanced bladder cancer for adoptive immunotherapy
Authors: Qiang John Li et al.
Session Type: Poster Session A
Abstract Number: A05
Location: Grand Hyatt Denver
Date/Time: Sunday, May 19, from 12:30 p.m. – 3:00 p.m. MDT

20th Annual B. Riley FBR Investor Conference in Beverly Hills, CA, May 22-23, 2019
Location: The Beverly Hilton Hotel
Date/Time: Thursday, May 23, at 9:00 a.m. PDT
A live and archived webcast of the presentation will be available by visiting the Investors section of Iovance Biotherapeutics’ website at View Source